# Sucunamostat hydrate

Cat. No.: HY-130126

Molecular Formula:  $C_{22}H_{22}N_4O_8.xH_2O$ Target: Enteropeptidase

Pathway: Metabolic Enzyme/Protease

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

**Product** Data Sheet

## **BIOLOGICAL ACTIVITY**

Description	$Sucunamost at \ hydrate\ (SCO-792)\ is\ an\ orally\ active\ and\ reversible\ enteropeptidase\ inhibitor\ with\ IC_{50}s\ of\ 4.6\ nM\ and\ 5.4\ nM$
	for rat enteropeptidase and human enteropeptidase, respectively. Sucunamostat hydrate can slowly dissociate from
	enteropentidase in vitro and inhibit protein digestion in vivo <sup>[1]</sup> .

IC<sub>50</sub> & Target IC<sub>50</sub>: 4.6 nM (rat enteropeptidase), 5.4 nM (human enteropeptidase)<sup>[1]</sup>

In Vivo Sucunamostat hydrate (10 and 30 mg/kg; PO, single dosage) effectively and dose-dependently inhibits plasma branchedchain amino acids (BCAA) elevations induced by oral protein dosing in rats<sup>[1]</sup>.

Pharmacokinetic Parameters of Sucunamostat hydrate in male Sprague-Dawley rats<sup>[1]</sup>.

	PO (10 mg/kg)	IV (2 mg/kg)
C <sub>max</sub> (ng/mL)	6.60 ± 1.36	564 ± 58
T <sub>max</sub> (h)	1.7 ± 0.6	
AUC <sub>0-24</sub> (ng/mL·h)	54.1 ± 7.5	303 ± 23
AUC <sub>inf</sub> (ng/mL·h)	49.8 ± 5.4	304 ± 30
Vd <sub>SS</sub> (mL/kg)		1290 ± 299
CL <sub>p</sub> (mL/min/kg)		663 ± 66
bioavailability (%)	0.4	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

1]. Sasaki M, et al. Discovery an	and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. Pharmacol Res	s Perspect. 2019 Sep 4;7(5):e00517.
	Caution: Product has not been fully validated for medical applications. For res	earch use only.
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChe Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, US	

Page 2 of 2 www.MedChemExpress.com